Francis Medical Expands Vanquish System to Southeast with First Commercial Procedures
Event summary
- Francis Medical performed first commercial procedures using the Vanquish® Water Vapor Ablation System in the Southeast on April 16, 2026.
- Procedures were conducted at Johns Creek and Marietta Surgery Centers by urologists Drs. Neal Patel and Jason Lomboy of Advanced Urology.
- The Vanquish System received FDA clearance in November 2025 and is supported by early clinical data from the VAPOR 2 pivotal study.
- At six months, 91% of patients achieved clearance of clinically significant in-field disease with no device-related serious adverse events reported.
The big picture
Francis Medical's expansion into the Southeast with its Vanquish System marks a strategic milestone in bringing minimally invasive prostate cancer treatment options to more patients. The technology's potential to preserve urinary and sexual function positions it as a competitive alternative to traditional surgery or radiation, aligning with broader industry trends toward less invasive cancer therapies. The company's disciplined launch approach, coupled with growing physician confidence, suggests a measured but deliberate path to market penetration.
What we're watching
- Clinical Validation
- Whether early positive outcomes from the VAPOR 2 study will translate into sustained long-term efficacy and adoption.
- Geographic Expansion
- The pace at which Francis Medical can scale commercial procedures beyond the Southeast.
- Regulatory Clarity
- How the FDA's current clearance limitations may impact broader market acceptance and reimbursement dynamics.
Related topics